{"url_path":"/sec/lxeo/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-270275-index.html","accession_number":"0001193125-26-270275","cik":"0001907108","ticker":"LXEO","issuer_name":"Lexeo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-270275-index.html","primary_entity_key":"0001907108","primary_entity_name":"Lexeo Therapeutics, Inc."},"word_count":100,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n99.1\n\n \n\n[Press release issued by the Company on June 15, 2026](lxeo-ex99_1.htm)\n\n99.2\n\n \n\n[Corporate Presentation (LX2006), dated June 15, 2026, furnished herewith](lxeo-ex99_2.htm)\n\n99.3\n\n \n\n[Corporate Presentation, dated June 15, 2026](lxeo-ex99_3.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLexeo Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ R. Nolan Townsend\n\n \n\n \n\n \n\n R. Nolan Townsend, Chief Executive Officer"}